Because Mongolia has much higher liver disease burden than any other regions of the world, it is necessary to provide information on real-time situation of chronic liver disease in Mongolia. In this article, we reviewed studies performed in Mongolia from 2000 to 2011 on seroprevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) among healthy individuals and patients with chronic liver diseases, and on the practice patterns for the management of liver cirrhosis and hepatocellular carcinoma (HCC). According to previous reports, the seroprevalence of HBV and HCV in general population in Mongolia is very high (11.8% and 15% for HBV and HCV, respectively). Liver cirrhosis is also highly prevalent, and mortality from liver cirrhosis remained high for the past decade (about 30 deaths per 100,000 populations per year). Among patients with cirrhosis, 40% and 39% are positive for HBsAg and anti-HCV, respectively, and 20% are positive for both. The seroprevalence is similar for HCC and more than 90% of HCC patients are positive for either HBV or HCV. The incidence of HCC in Mongolia is currently among the highest in the world. The mortality from HCC is also very high (52.2 deaths per 100,000 persons per year in 2010). Partly due to the lack of established surveillance systems, most cases of HCC are diagnosed at an advanced stage. The mortality from liver cirrhosis and HCC in Mongolia may be reduced by implementation of antiviral therapy program and control of alcohol consumption.
INTRODUCTION
Mongolia has the highest incidence of hepatocellular carcinoma (HCC) and liver cirrhosis (LC) worldwide (Fig. 1) . HCC occurs in 61.9 patients per 100,000 population each year, and LC occurs in 350 patients per 100,000, and its high occurrence has been attributed to the high prevalence of chronic viral hepatitis [1] . We explain the current situation regarding HCC and LC in Mongolia.
ETIOLOGY
The hepatitis B (HBV) and C viruses (HCV) are highly prevalent in Mongolia. The seroprevalence of HBV is 11.8% in the unvaccinated population (meta-analysis of eight studies) [2] , and that of HCV is 15.6% in the apparently healthy population [3] .
The prevalence of chronic HCV infection in Mongolia is strikingly high considering that the global HCV carrier prevalence is estimated to be about 3%, ranging from 0.1 to 10% or more [4] . Therefore, Mongolia has the highest prevalence (> 15%) of HCV and (> 10%) HBV infection, along with Egypt and Tanzania [5, 6] . This high prevalence is attributed to improper sterilization and disinfection of medical and dental equipment that might contribute to the spread of hepatitis viruses [3] .
Interestingly, most HCV infections are caused by genotype 1 (98.8%) in patients with chronic hepatitis, and genotype 2 infection is very rare (1.2%) [3] . In this regard, improvements in blood safety as well as the development and execution of strict disinfection and sterilization guidelines for health-related procedures such as phlebotomy, injection, and dental and surgical manipulations are required to control the spread of hepatitis viruses in Mongolia. Besides chronic hepatitis C, Mongolia is confronted with a high prevalence of chronic hepatitis B (Table 1 ). The HBV surface antigen (HBsAg) prevalence is 9-10% of healthy individuals in Mongolia [7] . With such a high HBV carrier rate in the general population, HBV infection and its associated complications pose serious health problems. To reduce the rate of HBV infection via mother-to-baby transmission during infancy, the Mongolian government launched a universal HBV immunization program in 1991. Most HBV infections are caused by genotype D (88.8%). Genotypes A, B, and C infection are rare at 0.9, 0.9, and 6.0% respectively [8] . One study demonstrated that 10-50% of HBV immunization attempts failed and that HBV vaccine failure is not associated with HBV mutants but is often associated with an inability to simultaneously administer the vaccine and immunoglobulin at birth.
MORBIDITY, MORTALITY, AND SURVIVAL OF HCC AND LC
LC is highly prevalent in Mongolia (Table 2 ). Most LC is attributable to HCV, HBV, and hepatitis D virus (HDV), and a small portion is due to alcohol (Fig. 2 ).
Among patients with cirrhosis, 40% (95% confidence interval [CI], 37 to 43) are HBsAg+; 39% (95% CI, 36 to 42) are antiHCV+, 20% (95% CI, 18 to 23) are dual+, and 1% are negative [9] (Fig. 3) . In the last 10 years, cancers have been second among the causes of mortality in Mongolia. According to the 2010 national statistics, HCC is the most common malignancy, representing 44.2% of all cancers in Mongolia (Fig. 4 ). An increase in the incidence and deaths from HCC has been observed in recent years (Fig. 5) . The incidence of HCC is six times higher than the global average (Fig. 6 ). In Europe, the USA, and Japan, HCV is the predominant cause of development of HCC, whereas HBV infection is the main cause of HCC in Korea. Mortality in males is mainly due to cancers of the liver and stomach and in females it is most commonly due to liver and cervical cancers. Higher incidences of cancer are observed in adults aged 45 to 60 years ( Kurbanov et al. [10] Oyunsuren et al. [11] Oyunsuren et al. [12] Tsatsralt-Od et al. [8] Jazag et al. [13] HCV Incidence per 100,000 population 1 9 6 7 -1 9 7 1 1 9 7 2 -1 9 7 6 1 9 7 7 -1 9 8 1 1 9 8 2 -1 9 8 6 1 9 8 7 -1 9 9 1 1 9 9 2 -1 9 9 6 1 9 9 7 -2 0 0 1 2 0 0 2 -2 0 0 5 2 0 0 6 -2 0 1 0 hospitals perform 2-3 phase contrast CTs at this time.
In our recent as-yet unpublished study, the most-used diagnostic imaging modality for the first examination was US in all patients. The second-most common imaging modality was contrast-enhanced CT in 58 (44.9%) patients followed by contrast-enhanced CT and hepatic angiography in 32 (24.8%). (Fig. 7) .
Two surgical methods are used for major hepatectomies: the conventional and Glissonian pedicle approaches (Fig. 8) . The Glissonian pedicle approach was introduced in the last few years and has already produced positive results. While average blood loss was 358.5 mL in the Glissonian pedicle approach group, it was 747.5 mL during conventional liver resection. Patients who underwent liver resection using a Glissonian pedicle approach survived longer than those who received the conventional method (Fig. 9) . person is needed for a full set of diagnostic tests. A total of 12,267 US$/person is needed for 48-week peginterferon treatment including 1 month of hospital stay, whereas classic interferon treatment costs 2,953 US$/ person. Currently, with no insurance coverage for viral treatment, a total of 6.34 billion US$ is required to treat every citizen with pegylated interferon, and 1.52 billion US$ is needed to treat using conventional interferon therapy. The financial burden of HCV is so great that 41 life-years are needed for middle-class Mongolian patients to save enough money to have the latest hepatitis treatment. Poverty and insurance policies are the most to blame for this dire situation. HCV treatment will cost more than the country's gross domestic product, which stands at 4.2 billion US$ as of 2009. As more oral treatment agents become available in the coming years, it is likely that HCV treatment costs will increase before they decrease. Thus, it is crucial for the World Health Organization, pharmaceutical companies, and other international organizations to help countries like Mongolia fight HCV. Treatment for HBV has improved recently. Lamivudine was registered 3 years ago, and tenofovir disoproxil fumarate is undergoing registration by the Mongolian Federal Drug Administration. Adefovir, telbivudine, and entecavir are not yet registered. Despite the affordable price of lamivudine for most patients, other regimens remain too expensive for low-income patients. Although there is no cure for HDV, upcoming trials show promise for peg-interferon only, peg-interferon in combination with tenofovir, or tenofovir alone treatments.
DISCUSSION
Alcohol consumption remains one of the major causes of HCC in Mongolia, and this issue has to be addressed by both doctors and the government. Poverty is the major cause of excess alcohol consumption, according to many studies. The flourishing alcohol business has to be controlled by the government and anti-alcohol laws must be implemented.
With the elimination of causes and improvements in diagnosis and treatment, we believe that a reduction in mortality from HCC and LC by at least by 30% is possible in the near future.
